直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Article

Preparing a Promising Drug Candidate for ANDA Litigation - Part 1

September 3, 2018

Life Science Leader

By Michael J. Flibbert; Megan Leinen Johns

Having a promising drug candidate in clinical trials can be an exciting time for a pharmaceutical company. It is also a time when it pays to think ahead on how best to position that drug candidate for patent coverage and how to withstand likely patent challenges. Most new drugs receive about 12 to 16 years of market exclusivity from the time of FDA approval. With patent protection serving an integral role in maintaining market exclusivity against generic competition, you need to understand how your actions may potentially affect patent coverage and enforcement. In this article Finnegan attorneys Mike Flibbert and Megan Leinen Johns discuss how to prepare a drug candidate for ANDA litigation.

Click here to read the full article. 

Related Practices

Global IP Enforcement, Litigation, and Trials

Branded Hatch-Waxman (ANDA) Litigation and Trials

Related Industries

Life Sciences

Pharmaceutical

Related Offices

Washington, DC

Related Professionals

Michael J. Flibbert
Partner
Washington, DC
+1 202 408 4493
Email

Originally printed in Life Science Leader on September 3, 2018. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm's clients.

Related Insights

Conference

IAM Live: Navigating the UPC 2026

November 3, 2026

Paris

Conference

4th Global Patent Litigation FORUM

October 29, 2026

Munich

Conference

2026 AIPLA Annual Meeting

October 29-31, 2026

Washington, DC

Conference

2026 EDTX Bench Bar Conference

October 28-30, 2026

Fort Worth

Hybrid Conference

Intellectual Property Law Institute 2026 – California

October 19-20, 2026

San Francisco

Conference

31st Annual UMass Chan Research Retreat

October 14-15, 2026

Worcester

Hybrid Conference

Intellectual Property Law Institute 2026 – New York

September 28-29, 2026

New York

Conference

2026 IPO Annual Meeting

September 27-29, 2026

Toronto

Lecture

Resolving Patent Suits Without Settlement Payments

September 3, 2026

Virtual

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP